INKT

MiNK is a clinical-stage cell-therapy company with no product revenue in any year on record (FY2021–FY2025 all blank) and a cumulative deficit of -$157M. The entire investment case rests on unapproved science: lead asset agenT-797, an off-the-shelf allogeneic iNKT cell therapy now entering a randomized Phase 2 adaptive trial in severe pneumonia/ARDS, plus early CAR-iNKT programs (MiNK-215, MiNK-413). The MD&A's headline data — 70% 30-day survival in ventilated viral-ARDS patients vs ~10% controls — is genuinely interesting, but it is early Phase 1/2 signal, not a registrational read, and the company has 'treated nearly 100 patients' without a single approval or revenue dollar. This is an unknowable-outcome bet by the rubric's definition.

The balance sheet is the disqualifier. Stockholders' equity is -$14.2M (a deficit, even after a 27.4% YoY improvement), so the company is technically insolvent on a book basis. Cash is just $13.4M against an operating burn of -$5.93M; burn narrowed 38% YoY, but a randomized placebo-controlled Phase 2 will push spend the other way, implying roughly two years of runway at best and near-certain dilution ahead. Shares already grew 25.2% YoY to a tiny 4.97M float, and dependence on parent Agenus for G&A, lab space, IP and even insurance under the intercompany agreements adds a control/related-party overhang. Total assets of $14.2M are essentially the cash pile — there is no franchise value on the books yet.